Value-Based Oncology®
Value-Based Oncology®: September 2022
September 2021
February 2021
Advertisement
Advertisement
Trending on AJMC
1
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
2
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
3
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5